Evidence map›Paper›PMID 30760214›Full record

ArticleBMC neuroscience2019

Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.

Peggy Rentsch, Sandy Stayte, Gary P Morris, Bryce Vissel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Impact of aging on animal models of Parkinson's disease.Frontiers in aging neuroscience · 2022
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Peggy RentschFaculty of Medicine, University of New South Wales, High Street, Sydney, NSW, 2052, Australia.
Sandy StayteCentre for Neuroscience and Regenerative Medicine, Faculty of Science, University of Technology Sydney, PO Box 123, Broadway, Sydney, NSW, 2007, Australia.
Gary P MorrisCentre for Neuroscience and Regenerative Medicine, Faculty of Science, University of Technology Sydney, PO Box 123, Broadway, Sydney, NSW, 2007, Australia.
Bryce VisselCentre for Neuroscience and Regenerative Medicine, Faculty of Science, University of Technology Sydney, PO Box 123, Broadway, Sydney, NSW, 2007, Australia. bryce.vissel@uts.edu.au.ORCID 0000-0002-6518-1979
University of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurately assessing promising therapeutic interventions for human diseases depends, in part, on the reproducibility of preclinical disease models. With the development of transgenic mice, the rapid adaptation of a 6-OHDA mouse model of Parkinson's disease that was originally described for the use in rats has come with a lack of a comprehensive characterization of lesion progression. In this study we therefore first characterised the time course of neurodegeneration in the substantia nigra pars compacta and striatum over a 4 week period following 6-OHDA injection into the medial forebrain bundle of mice. We then utilised the model to assess the anti-dyskinetic efficacy of recombinant activin A, a putative neuroprotectant and anti-inflammatory that is endogenously upregulated during the course of Parkinson's disease.

resultsWe found that degeneration of fibers in the striatum was fully established within 1 week following 6-OHDA administration, but that the loss of neurons continued to progress over time, becoming fully established 3 weeks after the 6-OHDA injection. In assessing the anti-dyskinetic efficacy of activin A using this model we found that treatment with activin A did not significantly reduce the severity, or delay the time-of-onset, of dyskinesia.

conclusionFirst, the current study concludes that a 3 week duration is required to establish a complete lesion of the nigrostriatal tract following 6-OHDA injection into the medial forebrain bundle of mice. Second, we found that activin A was not anti-dyskinetic in this model.

Indexed as

ActivinsAnimalsAnti-Inflammatory Agents, Non-SteroidalAntiparkinson AgentsDisease ProgressionDyskinesia, Drug-InducedLevodopaMaleMedial Forebrain BundleMice, Inbred C57BLNeurodegenerative DiseasesNeuronsNeuroprotective AgentsOxidopamineParkinsonian DisordersRandom Allocationactivin AActivinsAnti-Inflammatory Agents, Non-SteroidalAntiparkinson AgentsLevodopaNeuroprotective AgentsOxidopamineAbnormal involuntary movementsNeuroinflammationParkinson’s diseaseStereologyStriatumSubstantia nigra pars compacta

Identifiers

PMID30760214
PMCPMC6374903
OpenAlexW2924973872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.